Talphera Inc 2026年季度报告

FORM 10-Q For the quarterly period ended March 31, 2026 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. TALPHERA, INC.(Exact name of registrantas specified in its charter) 1850 Gateway Drive, Suite 175San Mateo, CA 94404(650) 216-3500(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) Securities registered pursuant to Section 12(b) of the Act: Name of Each Exchange on Which Registered: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filingrequirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit suchfiles).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company”in Rule12b-2of the Exchange Act.: If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any newor revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2)Yes☐No☒ As of May 7, 2026, the number of outstanding shares of the registrant’s common stock was 51,899,648. TALPHERA, INC.QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2026 TABLE OF CONTENTS Unless the context indicates otherwise, the terms “Talphera,” “we,” “us” and “our” refer to Talphera, Inc., and its consolidated subsidiary.“Niyad” and “Fedsyra” are trademarks, and “Zalviso” are registered trademarks, all owned by Talphera, Inc. This Quarterly Report alsocontains trademarks and trade names that are the property of their respective owners. Forward-Looking Statements This Quarterly Report on Form10-Q, or Form 10-Q, contains “forward-looking statements” within the meaning of Section21E of theSecurities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the “safe harbor” created by that section. Theforward-looking statements in this Form 10-Q are contained principally under “Part I. Financial Information - Item 2. Management’sDiscussion and Analysis of Financial Condition and Results of Operations” and “Part II. Other Information - Item 1A. Risk Factors”. In somecases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,”“plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or othercomparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties andother factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the informationexpressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-lookingstatement contained in this Form 10-Q, we caution you that these statements are based on a combination of facts and factors currently knownby us and our projections of the future, about which we cannot be certain. Many important factors affect our ability to achieve our objectives,including: •our ability to obtain additional required financing and to continue as a going concern;•our ability to maintain listing of our securities trading on the Nasdaq exchange;•our ability to manage our operating costs and reduce our cash burn;•the accuracy of our estimates regarding the sufficiency of our cash resources, future revenues, expenses, and capital requirements;•the historical performance and high volatility in the market price of our common stock;•macroeconomic uncertainties, including tariffs, inflationary pressures, domestic and global supply chain disruptions, laborshortages, significant volatility in global markets, and recession risks;•our ability to conduct ourselves, or through a contract research organization, clinical trials in a timely and effective manner toadvance the development of our product candidates, including our lead nafamostat developmental product candidate, Niyad®;•our ability to successfully file for and obtain regulatory approval for, and then successfully launch